{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:41:40Z","timestamp":1780947700435,"version":"3.54.1"},"reference-count":80,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"vor","delay-in-days":238,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006087","name":"Direcci\u00f3n General de Asuntos del Personal Acad\u00e9mico, Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.csbj.2022.08.056","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T02:36:52Z","timestamp":1662604612000},"page":"5181-5192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Subtle structural differences of nucleotide analogs may impact SARS-CoV-2 RNA-dependent RNA polymerase and exoribonuclease activity"],"prefix":"10.34133","volume":"20","author":[{"given":"Abraham","family":"Madariaga-Maz\u00f3n","sequence":"first","affiliation":[{"name":"Instituto de Qu\u00edmica Unidad M\u00e9rida, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Carretera M\u00e9rida-Tetiz Km. 4.5, Uc\u00fa, Yucat\u00e1n, Mexico"},{"name":"Instituto de Investigaciones en Matem\u00e1ticas Aplicadas y en Sistemas Unidad M\u00e9rida, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Sierra Papac\u00e1l M\u00e9rida, Yucat\u00e1n 97302, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 J.","family":"Naveja","sequence":"additional","affiliation":[{"name":"Instituto de Qu\u00edmica Unidad M\u00e9rida, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Carretera M\u00e9rida-Tetiz Km. 4.5, Uc\u00fa, Yucat\u00e1n, Mexico"},{"name":"Institute for Molecular Biology and University Cancer Center (UCT) Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Becerra","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Alberto Campillo-Balderas","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Hern\u00e1ndez-Morales","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"J\u00e1come","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lazcano","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Mexico City, Mexico"},{"name":"El Colegio Nacional, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Martinez-Mayorga","sequence":"additional","affiliation":[{"name":"Instituto de Qu\u00edmica Unidad M\u00e9rida, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Carretera M\u00e9rida-Tetiz Km. 4.5, Uc\u00fa, Yucat\u00e1n, Mexico"},{"name":"Instituto de Investigaciones en Matem\u00e1ticas Aplicadas y en Sistemas Unidad M\u00e9rida, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Sierra Papac\u00e1l M\u00e9rida, Yucat\u00e1n 97302, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-00104-8"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107058"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2006.01.017"},{"key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"e0246981","DOI":"10.1371\/journal.pone.0246981","article-title":"Structural analysis of viral ExoN domains reveals polyphyletic hijacking events","volume":"16","author":"Cruz-Gonz\u00e1lez A.","year":"2021","unstructured":"Cruz-Gonz\u00e1lez A., Mu\u00f1oz-Velasco I., Cottom-Salas W., Becerra A., Campillo-Balderas J.A., Hern\u00e1ndez-Morales R. et al: Structural analysis of viral ExoN domains reveals polyphyletic hijacking events. PLoS ONE 2021; 16: e0246981.","journal-title":"PLoS ONE"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2008281117"},{"key":"e_1_3_5_7_2","first-page":"E162","article-title":"Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA","volume":"115","author":"Ferron F.","year":"2017","unstructured":"Ferron F., Subissi L., de Morais A.T.S., Le N.T.T., Sevajol M., Gluais L. et al: Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc Natl Acad Sci U S A 2017; 115: E162.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","unstructured":"Cohen J. Vaccines that can protect against many coronaviruses could prevent another pandemic. Science (1979) 2021. https:\/\/doi.org\/10.1126\/science.abi9939.","DOI":"10.1126\/science.abi9939"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","unstructured":"Rona G Zeke A Miwatani-Minter B de Vries M Kaur R Schinlever A et al. The NSP14\/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target. Cell Death Different 2021 29:2 2021;29:285\u201392. https:\/\/doi.org\/10.1038\/s41418-021-00900-1.","DOI":"10.1038\/s41418-021-00900-1"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jama.2021.2828","article-title":"The potential future of the COVID-19 pandemic: will SARS-CoV-2 become a recurrent seasonal infection?","volume":"325","author":"Murray C.J.L.","year":"2021","unstructured":"Murray C.J.L. and Piot P.: The potential future of the COVID-19 pandemic: will SARS-CoV-2 become a recurrent seasonal infection?. JAMA 2021; 325: 1249.","journal-title":"JAMA"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","unstructured":"Coronaviridae. Virus Taxonomy 2012:806\u201328. https:\/\/doi.org\/10.1016\/B978-0-12-384684-6.00068-9.","DOI":"10.1016\/B978-0-12-384684-6.00068-9"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.virol.2018.08.010","article-title":"Description and initial characterization of metatranscriptomic nidovirus-like genomes from the proposed new family Abyssoviridae, and from a sister group to the Coronavirinae, the proposed genus Alphaletovirus","volume":"524","author":"Bukhari K.","year":"2018","unstructured":"Bukhari K., Mulley G., Gulyaeva A.A., Zhao L., Shu G., Jiang J. et al: Description and initial characterization of metatranscriptomic nidovirus-like genomes from the proposed new family Abyssoviridae, and from a sister group to the Coronavirinae, the proposed genus Alphaletovirus. Virology 2018; 524: 160.","journal-title":"Virology"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.REV120.013930"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139001","article-title":"Structural analysis of monomeric RNA-dependent polymerases: evolutionary and therapeutic implications","volume":"10","author":"J\u00e1come R.","year":"2015","unstructured":"J\u00e1come R., Becerra A., de Le\u00f3n S.P. and Lazcano A.: Structural analysis of monomeric RNA-dependent polymerases: evolutionary and therapeutic implications. PLoS ONE 2015; 10.","journal-title":"PLoS ONE"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2015.09.026"},{"key":"e_1_3_5_16_2","article-title":"Structure unveils relationships between RNA virus polymerases","volume":"13","author":"M\u00f6nttinen H.A.M.","year":"2021","unstructured":"M\u00f6nttinen H.A.M., Ravantti J.J. and Poranen M.M.: Structure unveils relationships between RNA virus polymerases. Viruses 2021; 13.","journal-title":"Viruses"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msu219"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","unstructured":"Kirchdoerfer RN Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun 2019 10:1 2019;10:1\u20139. https:\/\/doi.org\/10.1038\/s41467-019-10280-3.","DOI":"10.1038\/s41467-019-10280-3"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb7498"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00239-022-10059-z"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1093\/nar\/gkv838","article-title":"Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses","volume":"43","author":"Lehmann K.C.","year":"2015","unstructured":"Lehmann K.C., Gulyaeva A., Zevenhoven-Dobbe J.C., Janssen G.M.C., Ruben M., Overkleeft H.S. et al: Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses. Nucleic Acids Res 2015; 43: 8416.","journal-title":"Nucleic Acids Res"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3389\/fmicb.2019.01813","article-title":"The curious case of the nidovirus exoribonuclease: its role in RNA synthesis and replication fidelity","volume":"10","author":"Ogando N.S.","year":"2019","unstructured":"Ogando N.S., Ferron F., Decroly E., Canard B., Posthuma C.C. and Snijder E.J.: The curious case of the nidovirus exoribonuclease: its role in RNA synthesis and replication fidelity. Front Microbiol 2019; 10: 1813.","journal-title":"Front Microbiol"},{"key":"e_1_3_5_23_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003565","article-title":"Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics","volume":"9","author":"Smith E.C.","year":"2013","unstructured":"Smith E.C., Blanc H., Vignuzzi M. and Denison M.R.: Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog 2013; 9.","journal-title":"PLoS Pathog"},{"key":"e_1_3_5_24_2","doi-asserted-by":"crossref","unstructured":"Agostini ML Andres EL Sims AC Graham RL Sheahan TP Lu X et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018;9. https:\/\/doi.org\/10.1128\/MBIO.00221-18\/ASSET\/A3FF74B2-3D2F-4D32-8CFF-6F258D2C4B92\/ASSETS\/GRAPHIC\/MBO0011837620007.JPEG.","DOI":"10.1128\/mBio.00221-18"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1039\/D0CP05948J"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.10.018"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa331"},{"key":"e_1_3_5_28_2","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.647693","article-title":"Combining SARS-CoV-2 proofreading exonuclease and RNA-dependent RNA polymerase inhibitors as a strategy to combat COVID-19: a high-throughput in silico screening","volume":"12","author":"Khater S.","year":"2021","unstructured":"Khater S., Kumar P., Dasgupta N., Das G., Ray S. and Prakash A.: Combining SARS-CoV-2 proofreading exonuclease and RNA-dependent RNA polymerase inhibitors as a strategy to combat COVID-19: a high-throughput in silico screening. Front Microbiol 2021; 12.","journal-title":"Front Microbiol"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.07.027"},{"key":"e_1_3_5_30_2","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Morales R Becerra A Campillo-Balderas JA Cottom-Salas WF Cruz-Gonz\u00e1lez A J\u00e1come R et al. Structural biology of the SARS-CoV-2 replisome: evolutionary and therapeutic implications. Biomedical Innov Combat COVID-19 2022:65\u201382. https:\/\/doi.org\/10.1016\/B978-0-323-90248-9.00007-3.","DOI":"10.1016\/B978-0-323-90248-9.00007-3"},{"key":"e_1_3_5_31_2","doi-asserted-by":"crossref","unstructured":"Avery M.E.: Washington D.C.: National Academies Press 2000. https:\/\/doi.org\/10.17226\/9977.","DOI":"10.17226\/9977"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2021.03.112"},{"key":"e_1_3_5_33_2","first-page":"1192","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai Q.","year":"2020","unstructured":"Cai Q., Yang M., Liu D., Chen J., Shu D., Xia J. et al: Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020; 6: 1192.","journal-title":"Engineering (Beijing)"},{"key":"e_1_3_5_34_2","first-page":"239","article-title":"Sofosbuvir as a potential option for the treatment of COVID-19","volume":"91","author":"Nourian A.","year":"2020","unstructured":"Nourian A. and Khalili H.: Sofosbuvir as a potential option for the treatment of COVID-19. Acta Bio Medica : Atenei Parmensis 2020; 91: 239.","journal-title":"Acta Bio Medica : Atenei Parmensis"},{"key":"e_1_3_5_35_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106114","article-title":"Ribavirin therapy for severe COVID-19: a retrospective cohort study","volume":"56","author":"Tong S.","year":"2020","unstructured":"Tong S., Su Y., Yu Y., Wu C., Chen J., Wang S. et al: Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents 2020; 56.","journal-title":"Int J Antimicrob Agents"},{"key":"e_1_3_5_36_2","doi-asserted-by":"crossref","unstructured":"Painter WP Holman W Bush JA Almazedi F Malik H Eraut NCJE et al. Human Safety Tolerability and Pharmacokinetics of Molnupiravir a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. Antimicrob Agents Chemother 2021;65. https:\/\/doi.org\/10.1128\/AAC.02428-20.","DOI":"10.1128\/AAC.02428-20"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(04)00120-5"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c01277"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2021.01.035"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.013679"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AC120.015720"},{"key":"e_1_3_5_42_2","article-title":"Molnupiravir, an Oral Antiviral Treatment for COVID-19","author":"Fischer W.","year":"2021","unstructured":"Fischer W., Eron J.J., Holman W., Cohen M.S., Fang L., Szewczyk L.J. et al: Molnupiravir, an Oral Antiviral Treatment for COVID-19. MedRxiv 2021; .","journal-title":"MedRxiv"},{"key":"e_1_3_5_43_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.tibs.2021.05.006","article-title":"The enzymes for genome size increase and maintenance of large (+)RNA viruses","volume":"46","author":"Ferron F.","year":"2021","unstructured":"Ferron F., Sama B., Decroly E. and Canard B.: The enzymes for genome size increase and maintenance of large (+)RNA viruses. Trends Biochem Sci 2021; 46.","journal-title":"Trends Biochem Sci"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_3_5_45_2","article-title":"Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19","author":"Bhimraj A.","year":"2020","unstructured":"Bhimraj A., Morgan R.L., Shumaker A.H., Lavergne V., Baden L., Cheng V.C.C. et al: Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 2020; .","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_46_2","first-page":"1","article-title":"Efficacy and safety of sofosbuvir\/ledipasvir in treatment of patients with COVID-19; A randomized clinical trial","volume":"91","author":"Nourian A.","year":"2020","unstructured":"Nourian A., Khalili H., Ahmadinejad Z., Kouchak H.E., Jafari S., Manshadi S.A.D. et al: Efficacy and safety of sofosbuvir\/ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Acta Bio Medica : Atenei Parmensis 2020; 91: 1.","journal-title":"Acta Bio Medica : Atenei Parmensis"},{"key":"e_1_3_5_47_2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90551-6","article-title":"The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials","volume":"11","author":"Hassanipour S.","year":"2021","unstructured":"Hassanipour S., Arab-Zozani M., Amani B., Heidarzad F., Fathalipour M. and Martinez-de-Hoyo R.: The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep 2021; 11.","journal-title":"Sci Rep"},{"key":"e_1_3_5_48_2","doi-asserted-by":"crossref","unstructured":"Elfiky AA. Anti-HCV nucleotide inhibitors repurposing against COVID-19. Life Sci 2020;248. https:\/\/doi.org\/10.1016\/J.LFS.2020.117477.","DOI":"10.1016\/j.lfs.2020.117477"},{"key":"e_1_3_5_49_2","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-4-14","article-title":"The journey of remdesivir: from Ebola to COVID-19","volume":"9","author":"Pardo J.","year":"2020","unstructured":"Pardo J., Shukla A.M., Chamarthi G. and Gupte A.: The journey of remdesivir: from Ebola to COVID-19. Drugs Context 2020; 9.","journal-title":"Drugs Context"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100770"},{"key":"e_1_3_5_52_2","doi-asserted-by":"crossref","unstructured":"Kokic G Hillen HS Tegunov D Dienemann C Seitz F Schmitzova J et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun 2021 12:1 2021;12:1\u20137. https:\/\/doi.org\/10.1038\/s41467-020-20542-0.","DOI":"10.1038\/s41467-020-20542-0"},{"key":"e_1_3_5_53_2","doi-asserted-by":"crossref","unstructured":"Malone B Campbell EA. Molnupiravir: coding for catastrophe. Nat Struct Mol Biol 2021 28:9 2021;28:706\u20138. https:\/\/doi.org\/10.1038\/s41594-021-00657-8.","DOI":"10.1038\/s41594-021-00657-8"},{"key":"e_1_3_5_54_2","doi-asserted-by":"crossref","unstructured":"Kabinger F Stiller C Schmitzov\u00e1 J Dienemann C Kokic G Hillen HS et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol 2021 28:9 2021;28:740\u20136. https:\/\/doi.org\/10.1038\/s41594-021-00651-0.","DOI":"10.1038\/s41594-021-00651-0"},{"key":"e_1_3_5_55_2","unstructured":"Merck and Ridgeback\u2019s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study - Merck.com n.d. https:\/\/www.merck.com\/news\/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat\/ (accessed March 16 2022)."},{"key":"e_1_3_5_56_2","unstructured":"Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir an Investigational Oral Antiviral Medicine in At Risk Adults With Mild-to-Moderate COVID-19 - Merck.com n.d. https:\/\/www.merck.com\/news\/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19\/ (accessed March 16 2022)."},{"key":"e_1_3_5_57_2","doi-asserted-by":"crossref","unstructured":"J\u00e1come R Campillo-Balderas JA Ponce de Le\u00f3n S Becerra A Lazcano A. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. Sci Rep 2020 10:1 2020;10:1\u20135. https:\/\/doi.org\/10.1038\/s41598-020-66440-9.","DOI":"10.1038\/s41598-020-66440-9"},{"key":"e_1_3_5_58_2","first-page":"5206","article-title":"Inhibitors of the hepatitis C virus polymerase","volume":"7","author":"Eltahla A.A.","year":"2015","unstructured":"Eltahla A.A., Luciani F., White P.A., Lloyd A.R. and Bull R.A.: Inhibitors of the hepatitis C virus polymerase. Mode Action Resistance Viruses 2015; 7: 5206.","journal-title":"Mode Action Resistance Viruses"},{"key":"e_1_3_5_59_2","article-title":"In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase","author":"Doharey P.K.","year":"2021","unstructured":"Doharey P.K., Singh V., Gedda M.R., Sahoo A.K., Varadwaj P.K. and Sharma B.: In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase. J Biomol Struct Dyn 2021; .","journal-title":"J Biomol Struct Dyn"},{"key":"e_1_3_5_60_2","doi-asserted-by":"crossref","unstructured":"Jockusch S Tao C Li X Anderson TK Chien M Kumar S et al. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antiviral Res 2020;180. https:\/\/doi.org\/10.1016\/J.ANTIVIRAL.2020.104857.","DOI":"10.1016\/j.antiviral.2020.104857"},{"key":"e_1_3_5_61_2","doi-asserted-by":"crossref","unstructured":"Castanares-Zapatero D Chalon P Kohn L Dauvrin M Detollenaere J Maertens de Noordhout C et al. Pathophysiology and mechanism of long COVID: a comprehensive review. 2022;54:1473\u201387. https:\/\/doi.org\/10.1080\/07853890.2022.2076901.","DOI":"10.1080\/07853890.2022.2076901"},{"key":"e_1_3_5_62_2","doi-asserted-by":"crossref","unstructured":"Lopez-Leon S Wegman-Ostrosky T Perelman C Sepulveda R Rebolledo PA Cuapio A et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Scientific Reports 2021 11:1 2021;11:1\u201312. https:\/\/doi.org\/10.1038\/s41598-021-95565-8.","DOI":"10.1038\/s41598-021-95565-8"},{"key":"e_1_3_5_63_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2500\/aap.2022.43.220018","article-title":"Long COVID: A proposed hypothesis-driven model of viral persistence for the pathophysiology of the syndrome","volume":"43","author":"Buonsenso D.","year":"2022","unstructured":"Buonsenso D., Piazza M., Boner A.L. and Bellanti J.A.: Long COVID: A proposed hypothesis-driven model of viral persistence for the pathophysiology of the syndrome. Allergy Asthma Proc 2022; 43: 187.","journal-title":"Allergy Asthma Proc"},{"key":"e_1_3_5_64_2","doi-asserted-by":"crossref","unstructured":"Phetsouphanh C Darley DR Wilson DB Howe A Munier CML Patel SK et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 2022 23:2 2022;23:210\u20136. https:\/\/doi.org\/10.1038\/s41590-021-01113-x.","DOI":"10.1038\/s41590-021-01113-x"},{"key":"e_1_3_5_65_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-022-07153-4","article-title":"Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19","volume":"22","author":"Tejerina F.","year":"2022","unstructured":"Tejerina F., Catalan P., Rodriguez-Grande C., Adan J., Rodriguez-Gonzalez C., Mu\u00f1oz P. et al: Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect Dis 2022; 22: 1.","journal-title":"BMC Infect Dis"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.04.037"},{"key":"e_1_3_5_67_2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijid.2021.04.068","article-title":"Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach","volume":"107","author":"D\u2019Abramo A.","year":"2021","unstructured":"D\u2019Abramo A., Vita S., Maffongelli G., Mariano A., Agrati C., Castilletti C. et al: Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. Int J Inf Dis 2021; 107: 247.","journal-title":"Int J Inf Dis"},{"key":"e_1_3_5_68_2","article-title":"Perpetually positive: post-COVID interstitial lung disease in an immunocompromised patient with diffuse large B-cell lymphoma","volume":"9","author":"Dayco J.S.","year":"2021","unstructured":"Dayco J.S., El-Reda Z., Sumbal N., Alhusain R. and Raheem S.: Perpetually positive: post-COVID interstitial lung disease in an immunocompromised patient with diffuse large B-cell lymphoma. J Invest Med High Impact Case Rep 2021; 9.","journal-title":"J Invest Med High Impact Case Rep"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab622"},{"key":"e_1_3_5_70_2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/d41586-022-00112-8","article-title":"Why scientists are racing to develop more COVID antivirals","volume":"601","author":"Kozlov M.","year":"2022","unstructured":"Kozlov M.: Why scientists are racing to develop more COVID antivirals. Nature 2022; 601: 496.","journal-title":"Nature"},{"key":"e_1_3_5_71_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19 \u2014 interim WHO solidarity trial results","volume":"384","author":"WHO Solidarity Trial Consortium","year":"2021","unstructured":"WHO Solidarity Trial Consortium : Repurposed antiviral drugs for covid-19 \u2014 interim WHO solidarity trial results. N Engl J Med 2021; 384: 497.","journal-title":"N Engl J Med"},{"key":"e_1_3_5_72_2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/d41586-022-01602-5","article-title":"New COVID drugs face delays as trials grow more difficult","volume":"606","author":"Sidik S.M.","year":"2022","unstructured":"Sidik S.M.: New COVID drugs face delays as trials grow more difficult. Nature 2022; 606: 637.","journal-title":"Nature"},{"key":"e_1_3_5_73_2","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00222-22","article-title":"Remdesivir and GS-441524 retain antiviral activity against delta, omicron, and other emergent SARS-CoV-2 variants","volume":"66","author":"Pitts J.","year":"2022","unstructured":"Pitts J., Li J., Perry J.K., du Pont V., Riola N., Rodriguez L. et al: Remdesivir and GS-441524 retain antiviral activity against delta, omicron, and other emergent SARS-CoV-2 variants. Antimicrob Agents Chemother 2022; 66.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_74_2","doi-asserted-by":"crossref","unstructured":"Dagpunar J. Interim estimates of increased transmissibility growth rate and reproduction number of the Covid-19 B.1.617.2 variant of concern in the United Kingdom. MedRxiv 2021:2021.06.03.21258293. https:\/\/doi.org\/10.1101\/2021.06.03.21258293.","DOI":"10.1101\/2021.06.03.21258293"},{"key":"e_1_3_5_75_2","doi-asserted-by":"crossref","unstructured":"White JM Schiffer JT Bender Ignacio RA Xu S Kainov D Ianevski A et al. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. MBio 2021;12. https:\/\/doi.org\/10.1128\/MBIO.03347-21.","DOI":"10.1128\/mbio.03347-21"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.540150503"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1352(199905\/06)12:3<177::AID-JMR451>3.0.CO;2-Z"},{"key":"e_1_3_5_78_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1747-0285.2007.00605.x","article-title":"Atomic property fields: Generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR","volume":"71","author":"Totrov M.","year":"2008","unstructured":"Totrov M.: Atomic property fields: Generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR. Chem Biol Drug Des 2008; 71: 15.","journal-title":"Chem Biol Drug Des"},{"key":"e_1_3_5_79_2","article-title":"SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information","author":"Biasini M.","year":"2014","unstructured":"Biasini M., Bienert S., Waterhouse A., Arnold K., Studer G., Schmidt T. et al: SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 2014; .","journal-title":"Nucleic Acids Res"},{"key":"e_1_3_5_80_2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/pro.3330","article-title":"MolProbity: more and better reference data for improved all-atom structure validation","volume":"27","author":"Williams C.J.","year":"2018","unstructured":"Williams C.J., Headd J.J., Moriarty N.W., Prisant M.G., Videau L.L., Deis L.N. et al: MolProbity: more and better reference data for improved all-atom structure validation. Protein Science: A Publication of the Protein Society 2018; 27: 293.","journal-title":"Protein Science: A Publication of the Protein Society"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v048.i02"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037022003907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037022003907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2022.08.056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T15:49:38Z","timestamp":1779032978000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2022.08.056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":80,"alternative-id":["10.1016\/j.csbj.2022.08.056"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2022.08.056","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subtle structural differences of nucleotide analogs may impact SARS-CoV-2 RNA-dependent RNA polymerase and exoribonuclease activity","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2022.08.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.","name":"copyright","label":"Copyright"}]}}